Clinical Trials Logo

Uterine Cancer clinical trials

View clinical trials related to Uterine Cancer.

Filter by:

NCT ID: NCT02896413 Completed - Uterine Cancer Clinical Trials

The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

Start date: June 2, 2016
Phase: N/A
Study type: Interventional

Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.

NCT ID: NCT02725489 Completed - Breast Cancer Clinical Trials

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Start date: June 3, 2016
Phase: Phase 2
Study type: Interventional

In this study, the researchers want to learn more about Vigil and durvalumab in advanced women's cancers: 1) how much of Vigil in combination with durvalumab (MEDI4736) can be given with an acceptable level of side effects, 2) the effects of Vigil and durvalumab in combination (good and bad), 3) if Vigil will cause changes in cancer cells that may help durvalumab attack the cancer, and 4) whether or not Vigil and durvalumab will slow your cancer or stop your cancer from getting worse. Combining Vigil with durvalumab will allow the former to induce (or increase) the infiltration of activated T cells into tumors, and in addition, to enhance PD-L1 (programmed cell death ligand 1) expression. Consequently, the response rate of historically low or un-responsive cancer will be increased with the combination of Vigil and anti PD-L1.

NCT ID: NCT02714621 Completed - Ovarian Cancer Clinical Trials

MR-HIFU for Recurrent Gynaecological Cancer

HIFU-Gynae
Start date: May 2016
Phase: N/A
Study type: Interventional

The primary objective of this pilot study is to determine whether or not it is feasible to use MRgHIFU to treat symptomatic (pain, bleeding) recurrent pelvic malignancy with an acceptable safety profile when conventional treatment options are not available. The ultimate goal is to be able not only to offer a viable method of symptom palliation in patients with recurrent pelvic tumours and improve their quality of life; but also to control tumour growth and extend life in a group of relatively young patients with isolated local recurrence.

NCT ID: NCT02531997 Completed - Breast Cancer Clinical Trials

A Mind-body Intervention to Improve Body and/or Self Image

Start date: August 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if hypnotic relaxation therapy is a more effective intervention for improving self-image in women who have been diagnosed with breast or gynecologic cancer when compared to progressive muscle relaxation therapy.

NCT ID: NCT02465892 Completed - Breast Cancer Clinical Trials

Pillars4Life Trial

Pillars4Life
Start date: May 2015
Phase: N/A
Study type: Interventional

This study aims to explore whether cancer patients can benefit from completing the Pillars4Life online coping program. This randomized control trial will have half its subject completing the program and the other half receiving standard care in order to measure whether the program is beneficial in dealing with stress, anxiety, and particularly chronic pain that often accompany a cancer diagnosis.

NCT ID: NCT02458001 Not yet recruiting - Ovarian Cancer Clinical Trials

Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer

SAFFRON
Start date: July 2015
Phase: N/A
Study type: Interventional

Women affected by gynaecologic cancers are often not aware of sexual consequences of cancer and its treatment. Most do not receive appropriate advice or help to recover sexual function, and the impact on their sexuality may be profound. Despite this several potential therapies can be effective in helping recovery. A major challenge is informing and involving the patients in an appropriate and sensitive manner, and a further issue is the delivery of such therapies in busy and medically driven gynaecologic oncology clinics. It will use and adapt existing evidence based therapies for improving sexual function after cancer treatment and develop a model for delivering these in the NHS (United Kingdom National Health Service) setting. The model of 'stepped care' is adapted from that used nationally and successfully in the Increasing Access to Psychological Therapies (IAPT) programme. Assessment allows for 'stepping up and down', i.e. calibrating the type of help a woman receives according to need and her response to treatment already given.This study will develop and evaluate a 'stepped' system of interventions using elements of best available evidence, adapting existing interventions to help women recover their sexual feelings and activity, starting with simple methods, moving on to new talking treatments for more complex cases. The investigators address all gynaecologic cancers on the principle that sexual difficulty is the problem the investigators are treating, not the cancer of origin. Ongoing clinical assessment will be vital for the success of the stepped care model. The investigators will deliver training and supervision to enhance the skills needed by the Clinical Nursing Specialist (CNS). An important part of this study will be characterising the range of women and their willingness to participate in psychosexual help. One-to-one follow up interviews will inform the level of input required for any subsequent Randomised Control Trial (RCT). The investigators will use internationally recognised rating scales for rating sexual function, assess how illness and treatment affect mood and self esteem. The investigators will also measure the overall cost-effectiveness to the public sector of providing this treatment, compared to costs of subsequent use of health and social services. This pilot study will assess the feasibility of conducting a full scale investigation of a stepped therapy and indicate the potential benefits to the patients, their partners, and to the NHS generally.

NCT ID: NCT02349958 Recruiting - Ovarian Cancer Clinical Trials

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

HIPEC/IPHC
Start date: September 2006
Phase: Phase 2
Study type: Interventional

To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies: Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers). Mesotheliomas. GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix). To monitor the toxicities and complications of this treatment regimen. To measure treatment related QOL changes after IPHC.

NCT ID: NCT02209532 Completed - Cervical Cancer Clinical Trials

A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping

FILM
Start date: December 2015
Phase: N/A
Study type: Interventional

This is a randomized, prospective, open label, multicenter study to assess the safety and utility of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in patients with uterine and cervical malignancies who are undergoing LN mapping.

NCT ID: NCT02095847 Withdrawn - Uterine Cancer Clinical Trials

High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection

Start date: n/a
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if imaging (called a hysteroscopy) can be used to help guide tumor removal during a hysterectomy.

NCT ID: NCT02069769 Completed - Ovarian Cancer Clinical Trials

Ensuring Communication in Hospice by Oncology Study (ECHO)

Start date: January 2014
Phase: N/A
Study type: Interventional

The goal of this study is to determine if scheduled communication with the oncology team through phone calls is helpful to caregivers with the transition to hospice care.